Eczema (Atopic Dermatitis) Clinical Trials in Las Vegas

View 31 new treatments for Eczema (Atopic Dermatitis) in Las Vegas, NV, and nearby areas, such as Henderson. Every day, Power helps hundreds of eczema patients connect with leading medical research.
View 17 trials in Las Vegas
Filter (17)

Nemolizumab for Eczema

Galderma Clinic, Las Vegas + 3 more

Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description
Waitlist

No Placebo Trial

Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team

Rocatinlimab for Eczema

Amgen Clinic, Las Vegas + 1 more

This trial is testing a new medication called rocatinlimab to see if it works well and is safe when used alone. It targets patients who might benefit from a new treatment option.Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
MD
Study Director

Lebrikizumab for Eczema

Eli Lilly Clinic, Las Vegas + 1 more

This trial is testing the safety and effectiveness of lebrikizumab, a medication for eczema. It targets people with moderate-to-severe atopic dermatitis, including those from previous studies and new participants. Lebrikizumab works by blocking a protein that causes inflammation and itching.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 5 - 8 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

Rocatinlimab for Atopic Dermatitis

Amgen Clinic, Las Vegas + 2 more

This trial is testing a medication called rocatinlimab to see if it changes how well people respond to tetanus and meningococcal vaccines by measuring antibody levels.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
MD
Study Director

Rocatinlimab for Atopic Dermatitis

Amgen Clinic, Las Vegas + 3 more

This trial tests a new drug called rocatinlimab combined with common skin treatments on patients with eczema. The goal is to see if this combination works better than standard treatments alone by calming the immune system to reduce symptoms like redness and itching.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
MD
Study Director

Amlitelimab for Atopic Dermatitis (SHORE)

Sanofi Clinic, Las Vegas + 1 more

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe atopic dermatitis (AD) with a history of inadequate response of topical treatment, on background topical corticosteroid (TCS) and/or topical calcineurin inhibitor (TCI). The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared with placebo in participants with moderate to severe AD aged 12 years and older on background TCS and/or TCI. Study details include: At the end of the treatment period, participants will have an option to enter a separate study: the blinded extension study EFC17600 (ESTUARY). For participants not entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 44 weeks including a 2 to 4-week screening, a 24-week randomized double-blind period, and a 16-week safety follow-up. For participants entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 28 weeks including a 2 to 4-week screening and a 24-week randomized double-blind period. The total treatment duration will be up to 24 weeks. The total number of visits will be up to 10 visits (or 9 visits for those entering the blinded extension study EFC17600 (ESTUARY).Show More
Recruiting
Phase 3
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team

Rocatinlimab for Atopic Dermatitis/Eczema

Amgen Clinic, Las Vegas + 4 more

This trial is testing rocatinlimab to see if it is safe and can be tolerated by people with moderate-to-severe eczema. The medication works by calming the immune system to reduce skin inflammation and irritation.Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
MD
Study Director

Upadacitinib for Eczema

AbbVie Clinic, Las Vegas + 1 more

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
ABBVIE INC.
Study Director

Nemolizumab for Prurigo Nodularis

Galderma Clinic, Henderson + 1 more

This trial is testing the safety of nemolizumab, a medication for people with prurigo nodularis. Prurigo nodularis is a skin condition that causes itchy, hard lumps. Nemolizumab aims to reduce itching and swelling by blocking certain signals in the body.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team

Amlitelimab for Eczema

Sanofi Clinic, Henderson + 2 more

This trial is testing amlitelimab, a medication for adults with moderate to severe atopic dermatitis who were in a previous trial. The study aims to see if the medication is safe and effective over an extended time. Amlitelimab works by calming the immune system to reduce skin inflammation.Show More
Recruiting

No Placebo Trial

Phase 2 & 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team
Page 1 of 2

Frequently Asked Questions

How much do eczema clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do eczema clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across eczema trials in Las Vegas, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for eczema patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

Where in Las Vegas is research being conducted for eczema?

In Las Vegas, clinical trials for eczema are being conducted in various neighborhoods, with activity noted in the southern areas. Approximately 33 trials are ongoing as of 2024.

What promising new drugs are being tested?

In Las Vegas, eczema research is focusing on treatments like Monoclonal Antibodies and Janus Kinase (JAK) Inhibitors. Notable drugs being studied include Dupilumab, Tralokinumab, and Upadacitinib.